TP T-13i AST ALT ALP Y CTP LOH CHE CRP 8.7 id 0.4 mg/d 21 AWL 131U/L 257 LU/L 12 111/L 234 11J/L 344 IU/L 0.30 mid No K a BUN ORE UA 142 meq/1 4.3 meqa 108 meqa 15.8 met! 0.71 mg/di 5.0 mg/d CEA 5_5 n8/m1 CYFM 2.21 ng/mi SCC 1.02 ng/m1 NSE 8.38 nx/mi Pro GRP 23.0 pg/ml
1) Ichinose Y, Kato H, Koike T, et al. Overall survival and local recurrence of 406 completely resected stage fila--n2 non-small cell lung cancer patients : questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials. Lung Cancer 2001; 34: 29-36. 2) Martini N, Flehinger BJ, Zaman MB, et al. Results of resection in non--oat cell carcinoma of the lung with mediastinal lymph node metastases. Ann Surg 1983; 198: 386-396. 723-729. 4) Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage NA non-small-cell lung cancer. J Nati Cancer Inst 1994; 86: 673-680. 5) Rosell R, Gomez- Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994; 330: 153-158. 6) Depierre A, Mi 11 eron B, Moro-Sibi lot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and III a non-small-cell lung cancer. J Clin Oncol 2002; 20: 247-253. 7) Nagai K, Tsuchiya R, Mori T, et al. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg 2003; 126: 254-260. 8) Albain KS, Swann RS, Rusch VR, et al. Phase I[I study of concurrent chemotherapy and radiotherapy (CT/RT) vs. C[/RT followed by surgical resection for stage MA (p 2) non-small cell lung cancer(nsclc) : Outcomes update of North American Intergroup 0139 (RTOG 9309) [Abstract]. 7014. J Clin Onchol 2005; 23(Supple): 9) Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Ann Intern Med 1996; 125: 10) Kubota K, Furuse K, Kawahara M, et al. Role of radiotherapy in cotined modality treatment of locally advanced non-small-cell lung cancer. J Clin Oncol 1994; 12: 1547-1552. 11) Ichinose Y, Yoshimori K, Sakai H, et al. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res 2004; 10: 7860-7864. 12) Ohyanagi F, Yamamoto N, flori ike A, et al. Phase II study of TS-1(S) plus cisplatin (P) with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer(nsclc) [Abstract]. J Clin Onchol 2007; 25 (Supple) : 18070. 13) Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004; 350: 1713-1721. 14) The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin based-adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351-360.